Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × Breast Diseases × exemestane × Clear all

Phase

Status

Sponsor Class

INDUSTRY 4 OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 94 Neoplasm Metastasis 9 Ovarian Neoplasms 3 Carcinoma, Intraductal, Noninfiltrating 3 Breast Neoplasms, Male 3 Prostatic Neoplasms 2 Obesity 2 Carcinoma, Non-Small-Cell Lung 2 Breast Carcinoma In Situ 2 Breast Cancer Metastatic 2 Arthralgia 2 Triple Negative Breast Neoplasms 1 Sexuality 1 Recurrence 1 Primary Breast Cancer ER+ve 1 Premenopausal Breast Cancer 1 Patient Acceptance of Health Care 1 Pancreatic Neoplasms 1 Pain 1 Multiple Endocrine Neoplasia Type 1 1 Metastatic Beast Cancer 1 Locoregional Recurrence 1 Hyperglycemia 1 Human Epidermal Growth Factor 2 Negative Carcinoma of Breast 1 Hormone Receptor Positive Malignant Neoplasm of Breast 1 HER2-positive Breast Cancer 1 First Line Metastatic Breast Cancer 1 Estrogen-receptor Positive Invasive Metastatic Breast Cancer 1 Endometrial Neoplasms 1 ER+ Breast Cancer 1

Interventions

Letrozole 4 pyrotinib 3 palbociclib 3 Trastuzumab 3 Anastrozole 3 abemaciclib 2 Sodium Chloride 2 Exercise 2 Epirubicin 2 Docetaxel 2 Cyclophosphamide 2 Botulinum Toxins, Type A 2 sacubitril and valsartan sodium hydrate drug combination 1 ribociclib 1 pertuzumab 1 gadoterate meglumine 1 exemestane 1 Vinorelbine 1 Tomography, X-Ray Computed 1 Tamoxifen 1 Surveys and Questionnaires 1 Surgimend 1 Surgical Procedures, Operative 1 Paclitaxel 1 Mammaplasty 1 Liquid Biopsy 1 Leflunomide 1 Lapatinib 1 High-Energy Shock Waves 1 Goserelin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03910712 2019-04-10

Pyrotinib

Peking Union Medical College Hospital

Phase 2 Unknown

Breast Diseases, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡